Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
CLDXCelldex Therapeutics(CLDX) ZACKS·2024-11-07 07:30

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.25%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.59 per share when it actually produced a loss of $0.54, delivering a surprise of 8.47%.Over the last four quarters, the ...